Floatz logo

Tisagenlecleucel

Primary Mediastinal Large B Cell Lymphoma

SWOG Cancer Research NetworkCell therapyPhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Primary Mediastinal Large B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Inno-206
University of Washington
Phase 4BBB
(+)-VINCRISTINE
Sun Yat-sen University
Phase 4BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
Cyclophosphamide
University of Washington
Phase 4BBB
PREDNISONE TABLETS
University of Washington
Phase 3BB

View all 21 →

Same molecule, other indications

Tisagenlecleucel is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
Diffuse Large B Cell LymphomaDormant
BB
Indicative ·
64 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →